We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the wake of mounting concerns over drug safety, the FDA has started reviewing
the possibility of building a new adverse event reporting system (AERS).
New Jersey-based pharmaceutical giant Merck has announced it will close its
San Diego research unit offering the remaining 110 employees jobs elsewhere.
Peninsula Pharmaceuticals has delayed the pricing of its initial public offering
and entered into discussions with a pharmaceutical company regarding the potential
acquisition of Peninsula.
The Pittsburgh-area subsidiary of British drugmaker GlaxoSmithKline has filed
a lawsuit against Nicodrops to stop the California company from making what
it says are false claims about Nicodrops' anti-smoking product.
Pfizer and ActivX Biosciences, a wholly owned subsidiary of Tokyo-based Kyorin
Pharmaceutical, have entered into a strategic collaborative agreement encompassing
multiple projects ranging from discovery to developmental stage programs across
multiple research sites of Pfizer's Global Research and Development organization.
Onondaga County is suing 70 leading national pharmaceutical companies, claiming
they defrauded taxpayers of millions of dollars by overcharging Medicaid through
inflated drug prices.
Pfizer and Microsoft have filed parallel lawsuits against website operators
and spam advertisers that they say sell illegal cheap versions of Pfizer's erectile
dysfunction drug Viagra.
Hubei Tongji Benda Ebei Pharmaceutical Co., a subsidiary
of Amersin Life Sciences, has entered into a sales contract with Zhangjiang
Pharmacy Co. to supply 1.5 million doses of Ribavirin in injection form.
Pfizer has signed a deal to license a set of compounds from German-based drugmaker
Schering AG that could be developed into products to prevent heart attacks and
strokes.